Erratum: Evaluation of Long-Term Treatment Effect in a Type 1 Diabetes Intervention Trial: Differences After Stimulation With Glucagon or a Mixed Meal. Diabetes Care 2014;37:1384-1391. DOI: 10.2337/dc13-1392;Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: Differences after stimulation with glucagon or a mixed meal

Diabetes Care

Volumn 37, Issue 5, 2014, Pages 1384-1391

  Pozzilli, Paolo ^a,b   Raz, Itamar ^c   Peled, Dana ^d   Elias, Dana ^d   Avron, Ann ^d   Tamir, Merana ^d   Eren, Rachel ^d   Dagan, Shlomo ^d   Cohen, Irun R ^e  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d Andromeda Biotech Ltd   (Israel)

^e WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; DIAPEP277; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE PANCREAS FUNCTION TEST; FEMALE; FOLLOW UP; GLUCAGON STIMULATION TEST; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MIXED MEAL TOLERANCE TEST; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; YOUNG ADULT;

EID: 84899116488     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-rt01a     Document Type: Erratum

References (29)

1. Rubenstein AH, Clark JL, Melani F, Steiner DF. Secretion of proinsulin C-peptide by pancreatic β cells and its circulation in blood. Nature 1969;224:697-699
2. Cernea S, Raz I, Herold KC, et al.; D-Cure Workshop. Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes Metab Res Rev 2009;25:694-704
3. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264 (Pubitemid 38044724)
4. Hendriksen C, Faber OK, Drejer J, Binder C. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon. Diabetologia 1977;13:615-619 (Pubitemid 8283450)
5. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998;128:517-523
6. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836 (Pubitemid 36929351)
7. Faber OK, Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes 1977;26:605-610 (Pubitemid 8149645)
8. Greenbaum CJ, Harrison LC; Immunology of Diabetes Society. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003;52:1059-1065 (Pubitemid 36523337)
9. Samols E, Marri G, Marks V. Promotion of Insulin Secretion by Glucagon. Lancet 1965;2:415-416
10. Cobelli C, Toffolo GM, Dalla Man C, et al. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 2007;293:E1-E15 (Pubitemid 47105910)
11. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al.; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971
12. Raz I, Ziegler AG, Linn T, et al.; DIA-AID 1 Writing Group. Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebocontrolled, randomized phase 3 trial. Diabetes Care 2014;37:1392-1400
13. Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP. Recommendations for the primary analysis of continuous endpoint in longitudinal clinical trials. Drug Inf J 2008;42:303-319
14. Siddiqui O, Hung HM, O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 2009;19:227-246
15. Besser RE, Shields BM, Casas R, Hattersley AT, Ludvigsson J. Lessons from the mixedmeal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care 2013;36:195-201
16. Faber OK, Madsbad S, Kehlet H, Binder C. Pancreatic beta cell secretion during oral and intravenous glucose administration. Acta Med Scand Suppl 1979;624:61-64 (Pubitemid 9127202)
17. Grodsky GM. Kinetics of insulin secretion. In Diabetes Mellitus: A Fundamental and Clinical Text. LeRoith D, Taylor SI, Olefsky JM, Eds. Philadelphia, Lippincott Williams & Wilkins, 2000, p. 2-11
18. Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes 2011;60:1599-1607
19. Samols E, Marri G, Marks V. Interrelationship of glucagon, insulin and glucose. The insulinogenic effect of glucagon. Diabetes 1966;15:855-866
20. Fraser RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycaemia slows gastric emptying in type 1 (insulindependent) diabetes mellitus. Diabetologia 1990;33:675-680 (Pubitemid 20377931)
21. De Block CE, De Leeuw IH, Pelckmans PA, Callens D, Máday E, Van Gaal LF. Delayed gastric emptying and gastric autoimmunity in type 1 diabetes. Diabetes Care 2002;25:912-917 (Pubitemid 41094292)
22. Schvarcz E, Palmér M, Aman J, Lindkvist B, Beckman KW. Hypoglycaemia increases the gastric emptying rate in patients with type 1 diabetes mellitus. Diabet Med 1993;10:660-663 (Pubitemid 23246786)
23. Sosenko JM, Palmer JP, Rafkin LE, et al.; Diabetes Prevention Trial-Type 1 Study Group. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes Care 2010;33:620-625
24. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188-2192
25. Kaas A, Andersen ML, Fredheim S, et al.; Hvidoere Study Group on childhood diabetes. Proinsulin, GLP-1, and glucagon are associated with partial remission in children and adolescents with newly diagnosed type 1 diabetes. Pediatr Diabetes 2012;13:51-58
26. Blandino-Rosano M, Perez-Arana G, Mellado-Gil JM, Segundo C, Aguilar-Diosdado M. Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1. J Mol Endocrinol 2008;41:35-44
27. Madsbad S, Sauerbrey N, Møller-Jensen B, Krarup T, Kühl C. Outcome of the glucagon test depends upon the prevailing blood glucose concentration in type I (insulin-dependent) diabetic patients. Acta Med Scand 1987;222:71-74 (Pubitemid 17128913)
28. Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski A. The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care 1981;4:579-585 (Pubitemid 12181458)
29. Bolli GB, Perriello G, Fanelli CG, De Feo P. Nocturnal blood glucose control in type I diabetes mellitus. Diabetes Care 1993;16 (Suppl. 3):71-89 (Pubitemid 23348323)